BNP Paribas Bonus Zert 6MK 30.12..../ DE000PC1UZM6 /
2024-09-23 5:20:34 PM | Chg.+0.360 | Bid6:03:03 PM | Ask6:03:03 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
97.650EUR | +0.37% | 97.710 Bid Size: 5,000 |
97.730 Ask Size: 5,000 |
MERCK CO. D... | - - | 2024-12-30 | Call |
GlobeNewswire
07-17
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
07-09
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination ...
GlobeNewswire
06-25
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of...
GlobeNewswire
06-18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06-06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
06-03
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
05-29
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-06
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
03-06
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...